Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Summit Therapeutics Inc. (SMMT)

NASDAQ: SMMT · Pharmaceutical Preparations · Miami, FL

Our rating: Cautious

Cautious reaffirmed at $14.19, moderate conviction, November 5, 2026.

Breaks if: The Cautious call is wrong if Summit's filings or disclosures show first U.S. commercial revenue exceeding zero, or if the company submits an NDA or receives a positive pivotal-trial readout, within the next 12 months — either would demonstrate the pipeline has cleared the threshold the $11.3 billion market cap requires and would prompt a full rating review. On the upside, if the stock sustains above $20 for more than 30 consecutive trading days without a corresponding commercial or regulatory event visible in the company's disclosures, the market is pricing something the available figures do not yet show and the call must be reconsidered.

Key figures

Market value$8.0B
Revenue, last 12 monthsn/a
Net income, last 12 months−$833M
Free cash flow, last 12 months−$527M
Price to earningsn/a
Free cash flow yield−6.6%
Dividend yield0.0%
Operating marginn/a
Return on equity−220.0%
Beta to the S&P 5001.47
Volatility, annualized199.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.26−$160M
June 30, 2026n/an/a$-0.28−$142M
March 31, 2026n/an/a$-0.24−$123M
December 31, 2025n/an/a$-0.28−$102M
September 30, 2025n/an/a$-0.31−$93M
June 30, 2025n/an/a$-0.76−$67M
March 31, 2025n/an/a$-0.09−$62M
December 31, 2024$0.00n/a$-0.09−$49M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

38 ledger entries and 43 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.